Rystiggo UCB Australia Pty Ltd T/A UCB Pharma Division of UCB Australia
Product name
Rystiggo
Accepted date
Nov-2023
Active ingredients
rozanolixizumab
Proposed indication
For the treatment of generalised myasthenia gravis (gMG).
Application type
A (new medicine)
Publication date
Nov-2023